Single-cell RNA sequencing in melanoma: what have we learned so far?

被引:10
作者
Lim, Su Yin [1 ,2 ,3 ]
Rizos, Helen [1 ,2 ]
机构
[1] Macquarie Univ, Fac Med Hlth & Human Sci, Macquarie Med Sch, Sydney, Australia
[2] Melanoma Inst Australia, Sydney, Australia
[3] Macquarie Univ, Level 1,75 Talavera Rd, Sydney 2109, Australia
来源
EBIOMEDICINE | 2024年 / 100卷
基金
英国医学研究理事会;
关键词
Immunotherapies; MAPK inhibitors; Dedifferentiation; Cellular states; IMMUNE CHECKPOINT INHIBITORS; ACQUIRED-RESISTANCE; METASTATIC MELANOMA; PD-1; BLOCKADE; BRAF-MUTANT; HETEROGENEITY; MECHANISMS; DIFFERENTIATION; PROGRESSION; LANDSCAPE;
D O I
10.1016/j.ebiom.2024.104969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past decade, there have been remarkable improvements in the treatment and survival rates of melanoma patients. Treatment resistance remains a persistent challenge, however, and is partly attributable to intratumoural heterogeneity. Melanoma cells can transition through a series of phenotypic and transcriptional cell states that vary in invasiveness and treatment responsiveness. The diverse stromal and immune contexture of the tumour microenvironment also contributes to intratumoural heterogeneity and disparities in treatment response in melanoma patients. Recent advances in single -cell sequencing technologies have enabled a more detailed understanding of melanoma heterogeneity and the underlying transcriptional programs that regulate melanoma cell diversity and behaviour. In this review, we examine the concept of intratumoural heterogeneity and the challenges it poses to achieving long-lasting treatment responses. We focus on the significance of next generation single -cell sequencing in advancing our understanding of melanoma diversity and the unique insights gained from single -cell studies. Copyright (c) 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:10
相关论文
共 75 条
  • [1] 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
    Ascierto, Paolo A.
    Dreno, Brigitte
    Larkin, James
    Ribas, Antoni
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Atkinson, Victoria
    Dutriaux, Caroline
    Garbe, Claus
    Hsu, Jessie
    Jones, Surai
    Li, Haocheng
    McKenna, Edward
    Voulgari, Athina
    McArthur, Grant A.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5225 - 5235
  • [2] Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression
    Bakhoum, Mathieu F.
    Francis, Jasmine H.
    Agustinus, Albert
    Earlie, Ethan M.
    Di Bona, Melody
    Abramson, David H.
    Duran, Mercedes
    Masilionis, Ignas
    Molina, Elsa
    Shoushtari, Alexander N.
    Goldbaum, Michael H.
    Mischel, Paul S.
    Bakhoum, Samuel F.
    Laughney, Ashley M.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [3] Dissecting the treatment-naive ecosystem of human melanoma brain metastasis
    Biermann, Jana
    Melms, Johannes C.
    Amin, Amit Dipak
    Wang, Yiping
    Caprio, Lindsay A.
    Karz, Alcida
    Tagore, Somnath
    Barrera, Irving
    Ibarra-Arellano, Miguel A.
    Andreatta, Massimo
    Fullerton, Benjamin T.
    Gretarsson, Kristjan H.
    Sahu, Varun
    Mangipudy, Vaibhav S.
    Nguyen, Trang T. T.
    Nair, Ajay
    Rogava, Meri
    Ho, Patricia
    Koch, Peter D.
    Banu, Matei
    Humala, Nelson
    Mahajan, Aayushi
    Walsh, Zachary H.
    Shah, Shivem B.
    Vaccaro, Daniel H.
    Caldwell, Blake
    Mu, Michael
    Wuennemann, Florian
    Chazotte, Margot
    Berhe, Simon
    Luoma, Adrienne M.
    Driver, Joseph
    Ingham, Matthew
    Khan, Shaheer A.
    Rapisuwon, Suthee
    Slingluff, Craig L., Jr.
    Eigentler, Thomas
    Roecken, Martin
    Carvajal, Richard
    Atkins, Michael B.
    Davies, Michael A.
    Agustinus, Albert
    Bakhoum, Samuel F.
    Azizi, Elham
    Siegelin, Markus
    Lu, Chao
    Carmona, Santiago J.
    Hibshoosh, Hanina
    Ribas, Antoni
    Canoll, Peter
    [J]. CELL, 2022, 185 (14) : 2591 - +
  • [4] Macrophage Polarization States in the Tumor Microenvironment
    Boutilier, Ava J.
    Elsawa, Sherine F.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
  • [5] Carlino MS, 2021, LANCET, V398, P1002, DOI 10.1016/S0140-6736(21)01206-X
  • [6] 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
    Carlino, Matteo S.
    Saunders, Catherine A. B.
    Haydu, Lauren E.
    Menzies, Alexander M.
    Curtis, C. Martin, Jr.
    Lebowitz, Peter F.
    Kefford, Richard F.
    Long, Georgina V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) : 395 - 402
  • [7] Fibroblasts in cancer: Unity in heterogeneity
    Chhabra, Yash
    Weeraratna, Ashani T.
    [J]. CELL, 2023, 186 (08) : 1580 - 1609
  • [8] Discovery of specialized NK cell populations infiltrating human melanoma metastases
    de Andrade, Lucas Ferrari
    Lu, Yuheng
    Luoma, Adrienne
    Ito, Yoshinaga
    Pan, Deng
    Pyrdol, Jason W.
    Yoon, Charles H.
    Yuan, Guo-Cheng
    Wucherpfennig, Kai W.
    [J]. JCI INSIGHT, 2019, 4 (23)
  • [9] The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance
    Diazzi, Serena
    Tartare-Deckert, Sophie
    Deckert, Marcel
    [J]. ONCOGENESIS, 2023, 12 (01)
  • [10] COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
    Dummer, Reinhard
    Flaherty, Keith T.
    Robert, Caroline
    Arance, Ana
    de Groot, Jan Willem B.
    Garbe, Claus
    Gogas, Helen J.
    Gutzmer, Ralf
    Krajsova, Ivana
    Liszkay, Gabriella
    Loquai, Carmen
    Mandala, Mario
    Schadendorf, Dirk
    Yamazaki, Naoya
    di Pietro, Alessandra
    Cantey-Kiser, Jean
    Edwards, Michelle
    Ascierto, Paolo A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4178 - +